Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Other Accumulated Expenses (2016 - 2025)

Cumberland Pharmaceuticals (CPIX) has disclosed Other Accumulated Expenses for 16 consecutive years, with $12.6 million as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses rose 3.14% to $12.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.6 million through Dec 2025, up 3.14% year-over-year, with the annual reading at $12.6 million for FY2025, 3.14% up from the prior year.
  • Other Accumulated Expenses hit $12.6 million in Q4 2025 for Cumberland Pharmaceuticals, up from $10.1 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $17.6 million in Q4 2022 to a low of $7.6 million in Q3 2021.
  • Historically, Other Accumulated Expenses has averaged $12.3 million across 5 years, with a median of $12.5 million in 2022.
  • Biggest five-year swings in Other Accumulated Expenses: dropped 24.67% in 2021 and later surged 102.9% in 2022.
  • Year by year, Other Accumulated Expenses stood at $8.7 million in 2021, then soared by 102.9% to $17.6 million in 2022, then decreased by 22.69% to $13.6 million in 2023, then fell by 9.9% to $12.3 million in 2024, then rose by 3.14% to $12.6 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for CPIX at $12.6 million in Q4 2025, $10.1 million in Q3 2025, and $10.1 million in Q2 2025.